Table 6 Major studies focus on the cfDNA plasma detection of ALK fusions

Kunimasa et al. [87]

PCR-based target sequencing ALK intron19

N = 20

50%

100%

n.r

Mezquita et al. [88]

Amplicon-based

(InVision™)

Retrospective

N = 59/6

ALK 78%/ROS1 100%

n.r

86%

Schwartzberg et al. [61]

NGS HiSeq® 2500 (Illumina)

Prospective

N = 115

50%

100%

96%

Cui S et al. [89]

Capture-based NGS

N = 39

54%

100%

n.r

Wang Ye et al. [90]

Capture-based NGS

N = 24

79%

100%

92%

Horn L et al. [92]

Hybrid-capture system NGS

(Resolution Bioscience)

(Phase I/II multicohort eXalt2 trial)

N = 76 (22 with paired pre-treatment tissue and plasma)

n.r

n.r

91%

Dagogo-Jack I et al. [91]

Hybrid-capture next-generation sequencing

Prospective

N = 22 with ALK progressive disease

86% ALK fusions

50% ALK mutations

n.r

100%

100%